Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Dec 21

PMID 31858116

Citations 7

Authors

Krishna Mohan Vadrevu

Venugopal Potula

Vasant Khalatkar

Niranjana S Mahantshetty

Atish Shah

Raches Ella

Affiliations

Soon will be listed here.

Abstract

Background: This study reports immunogenicity, safety, and interchangeability of a single-dose, inactivated, Vero-cell derived, JENVAC to the live-attenuated SA 14-14-2 vaccine in healthy children.

Methods: This phase 4, multicenter, open-label, randomized, control trial enrolled 360 children who were equally randomized to receive a single dose of either JENVAC or SA 14-14-2. Children were followed at various time points, until 2 years (day 720) postvaccination, upon which a subset from each group was divided and allocated to a receive a booster dose or the other vaccine.

Results: At all time points, immunological measures were statistically higher in the JENVAC group. In the interchangeability study, children receiving 2 doses of JENVAC reported significantly higher response compared with 2 doses of SA 14-14-2. No difference in adverse events was observed. These corroborate with excellent seroprotection after the first dose of an earlier JENVAC study.

Conclusions: A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year. We report appreciable interchangeability between both vaccines, with JENVAC/JENVAC combination exhibiting the highest immune response. JENVAC is now licensed as a single-dose Japanese encephalitis vaccine.

Citing Articles

Japanese encephlu emergence in Australia: the potential population at risk.

Khan A, Riaz R, Nadeem A, Amir A, Siddiqui T, Batool U Ann Med Surg (Lond). 2024; 86(3):1540-1549.

PMID: 38463109 PMC: 10923274. DOI: 10.1097/MS9.0000000000001739.

Japanese Encephalitis Vaccine Acceptance and Strategies for Travelers: Insights from a Scoping Review and Practitioners in Endemic Countries.

Asawapaithulsert P, Ngamprasertchai T, Kitro A Vaccines (Basel). 2023; 11(11).

PMID: 38006016 PMC: 10674921. DOI: 10.3390/vaccines11111683.

Japanese Encephalitis Virus: An Update on the Potential Antivirals and Vaccines.

Srivastava K, Jeswani V, Pal N, Bohra B, Vishwakarma V, Bapat A Vaccines (Basel). 2023; 11(4).

PMID: 37112654 PMC: 10146181. DOI: 10.3390/vaccines11040742.

A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects.

Dotiwala F, Upadhyay A Front Immunol. 2022; 13:940715.

PMID: 36177016 PMC: 9513542. DOI: 10.3389/fimmu.2022.940715.

The Outbreaks of Acute Encephalitis Syndrome in Uttar Pradesh, India (1978-2020) and Its Effective Management: A Remarkable Public Health Success Story.

Srivastava N, Deval H, Mittal M, Kant R, Bondre V Front Public Health. 2022; 9:793268.

PMID: 35223759 PMC: 8863615. DOI: 10.3389/fpubh.2021.793268.

References

Yu Y . Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine. 2010; 28(21):3635-41. DOI: 10.1016/j.vaccine.2010.02.105. View

Kedarnath N, Prasad S, DANDAWATE C, Koshy A, George S, Ghosh S . Isolation of Japanese encephalitis & West Nile viruses from peripheral blood of encephalitis patients. Indian J Med Res. 1984; 79:1-7. View

Kanagasabai K, Joshua V, Ravi M, Sabarinathan R, Kirubakaran B, Ramachandran V . Epidemiology of Japanese Encephalitis in India: Analysis of laboratory surveillance data, 2014-2017. J Infect. 2017; 76(3):317-320. DOI: 10.1016/j.jinf.2017.09.018. View

Sohn Y, Park M, Rho H, Chandler L, Shope R, Tsai T . Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine. 1999; 17(18):2259-64. DOI: 10.1016/s0264-410x(99)00006-7. View

Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T . Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine. 2015; 33(30):3600-4. DOI: 10.1016/j.vaccine.2015.05.037. View

Murhekar M, Oak C, Ranjan P, Kanagasabai K, Shinde S, Pandey A . Coverage & missed opportunity for Japanese encephalitis vaccine, Gorakhpur division, Uttar Pradesh, India, 2015: Implications for Japanese encephalitis control. Indian J Med Res. 2017; 145(1):63-69. PMC: 5460575. DOI: 10.4103/ijmr.IJMR_712_16. View

Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A . Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine. 2011; 29(14):2607-12. DOI: 10.1016/j.vaccine.2011.01.058. View

Abe M, Kuzuhara S, Kino Y . Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells. Vaccine. 2003; 21(17-18):1989-94. DOI: 10.1016/s0264-410x(02)00772-7. View

Dubischar K, Kadlecek V, Sablan J, Borja-Tabora C, Gatchalian S, Eder-Lingelbach S . Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region. Pediatr Infect Dis J. 2017; 36(9):898-904. DOI: 10.1097/INF.0000000000001615. View

10.

Xin Y, Ming Z, Peng G, Jian A, Min L . Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg. 1988; 39(2):214-7. DOI: 10.4269/ajtmh.1988.39.214. View

11.

Ohrr H, Tandan J, Sohn Y, Shin S, Pradhan D, Halstead S . Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet. 2005; 366(9494):1375-8. DOI: 10.1016/S0140-6736(05)67567-8. View

12.

Jain P, Prakash S, Khan D, Garg R, Kumar R, Bhagat A . Aetiology of acute encephalitis syndrome in Uttar Pradesh, India from 2014 to 2016. J Vector Borne Dis. 2018; 54(4):311-316. DOI: 10.4103/0972-9062.225835. View

13.

Patgiri S, Borthakur A, Borkakoty B, Saikia L, Dutta R, Phukan S . An appraisal of clinicopathological parameters in Japanese encephalitis and changing epidemiological trends in upper Assam, India. Indian J Pathol Microbiol. 2014; 57(3):400-6. DOI: 10.4103/0377-4929.138732. View

14.

Bandyopadhyay B, Bhattacharyya I, Adhikary S, Mondal S, Konar J, Dawar N . Incidence of Japanese encephalitis among acute encephalitis syndrome cases in West Bengal, India. Biomed Res Int. 2013; 2013:896749. PMC: 3844193. DOI: 10.1155/2013/896749. View

15.

Hutchins S, Jansen H, Robertson S, Evans P . Studies of missed opportunities for immunization in developing and industrialized countries. Bull World Health Organ. 1993; 71(5):549-60. PMC: 2393481. View

16.

Kadlecek V, Borja-Tabora C, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan Jr B . Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose. Pediatr Infect Dis J. 2018; 37(9):e233-e240. DOI: 10.1097/INF.0000000000002124. View

17.

Vashishtha V, Kalra A, Bose A, Choudhury P, Yewale V, Bansal C . Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years, India, 2013 and updates on immunization. Indian Pediatr. 2014; 50(12):1095-108. DOI: 10.1007/s13312-013-0292-9. View

18.

Mittal M, Bondre V, Murhekar M, Deval H, Rose W, Verghese V . Acute Encephalitis Syndrome in Gorakhpur, Uttar Pradesh, 2016: Clinical and Laboratory Findings. Pediatr Infect Dis J. 2018; 37(11):1101-1106. DOI: 10.1097/INF.0000000000002099. View

19.

Hombach J, Solomon T, Kurane I, Jacobson J, Wood D . Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine. 2005; 23(45):5205-11. DOI: 10.1016/j.vaccine.2005.07.002. View

20.

Hegde N, Gore M . Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. 2017; 13(6):1-18. PMC: 5529032. DOI: 10.1080/21645515.2017.1285472. View